Global Blood Therapeutics, Inc. (GBT): Price and Financial Metrics


Global Blood Therapeutics, Inc. (GBT): $33.49

0.21 (+0.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GBT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GBT POWR Grades


  • Value is the dimension where GBT ranks best; there it ranks ahead of 61.08% of US stocks.
  • GBT's strongest trending metric is Value; it's been moving down over the last 179 days.
  • GBT's current lowest rank is in the Sentiment metric (where it is better than 4.97% of US stocks).

GBT Stock Summary

  • GBT's price/sales ratio is 11.85; that's higher than the P/S ratio of 87.64% of US stocks.
  • With a year-over-year growth in debt of 186.83%, Global Blood Therapeutics Inc's debt growth rate surpasses 94.02% of about US stocks.
  • As for revenue growth, note that GBT's revenue has grown 57.31% over the past 12 months; that beats the revenue growth of 83.89% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Global Blood Therapeutics Inc are CERS, BLI, QUIK, SMTC, and PDEX.
  • Visit GBT's SEC page to see the company's official filings. To visit the company's web site, go to www.gbt.com.

GBT Valuation Summary

  • GBT's EV/EBIT ratio is -6.3; this is 121.5% lower than that of the median Healthcare stock.
  • GBT's price/sales ratio has moved NA NA over the prior 74 months.
  • GBT's price/sales ratio has moved NA NA over the prior 74 months.

Below are key valuation metrics over time for GBT.

Stock Date P/S P/B P/E EV/EBIT
GBT 2021-08-31 10.9 5.7 -6.7 -6.3
GBT 2021-08-30 10.6 5.5 -6.6 -6.2
GBT 2021-08-27 10.8 5.6 -6.7 -6.2
GBT 2021-08-26 10.7 5.6 -6.6 -6.2
GBT 2021-08-25 10.8 5.7 -6.7 -6.3
GBT 2021-08-24 11.1 5.8 -6.9 -6.5

GBT Growth Metrics

    Its 5 year price growth rate is now at 358.38%.
  • Its 5 year net income to common stockholders growth rate is now at -397.36%.
  • Its year over year net income to common stockholders growth rate is now at 14.24%.
Over the past 52 months, GBT's revenue has gone up $194,749,000.

The table below shows GBT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 194.749 -256.813 -303.091
2021-09-30 179.945 -233.953 -277.316
2021-06-30 164.782 -209.336 -266.209
2021-03-31 148.728 -212.496 -249.457
2020-12-31 123.803 -211.862 -247.553
2020-09-30 84.616 -229.133 -281.722

GBT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GBT has a Quality Grade of C, ranking ahead of 51.67% of graded US stocks.
  • GBT's asset turnover comes in at 0.277 -- ranking 165th of 682 Pharmaceutical Products stocks.
  • DRNA, OPK, and ICPT are the stocks whose asset turnover ratios are most correlated with GBT.

The table below shows GBT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.277 0.983 -0.711
2021-06-30 0.246 0.983 -0.700
2021-03-31 0.213 0.984 -0.628
2020-12-31 0.172 0.984 -0.573
2020-09-30 0.115 0.987 -0.594
2020-06-30 0.064 0.988 -0.580

GBT Price Target

For more insight on analysts targets of GBT, see our GBT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $72.47 Average Broker Recommendation 1.5 (Moderate Buy)

GBT Stock Price Chart Interactive Chart >

Price chart for GBT

GBT Price/Volume Stats

Current price $33.49 52-week high $40.69
Prev. close $33.28 52-week low $21.65
Day low $33.14 Volume 1,474,400
Day high $35.50 Avg. volume 1,352,129
50-day MA $27.67 Dividend yield N/A
200-day MA $29.93 Market Cap 2.18B

Global Blood Therapeutics, Inc. (GBT) Company Bio


Global Blood Therapeutics is a clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. The company was founded in 2012 and is based in San Francisco, California.


GBT Latest News Stream


Event/Time News Detail
Loading, please wait...

GBT Latest Social Stream


Loading social stream, please wait...

View Full GBT Social Stream

Latest GBT News From Around the Web

Below are the latest news stories about Global Blood Therapeutics Inc that investors may wish to consider to help them evaluate GBT as an investment opportunity.

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q4 2021 Results - Earnings Call Transcript

Global Blood Therapeutics, Inc. (GBT) Q4 2021 Earnings Conference Call February 23, 2022 04:30 PM ET Company Participants Ted Love - President and CEO Jeff Farrow - Chief Financial Officer David Johnson - Chief Commercial Officer Kim Smith-Whitley - EVP and Head of R&D Steven Immergut - SVP, Head of...

SA Transcripts on Seeking Alpha | February 24, 2022

Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.

Yahoo | February 24, 2022

Global Blood Therapeutics GAAP EPS of -$1.36 misses by $0.23, revenue of $56.1M beats by $0.65M

Global Blood Therapeutics press release (NASDAQ:GBT): Q4 GAAP EPS of -$1.36 misses by $0.23. Revenue of $56.1M (+35.8% Y/Y) beats by $0.65M. Cash, cash equivalents, and marketable securities totaled $734.8 million at December 31, 2021, compared with $560.9 million at December 31, 2020....

Seeking Alpha | February 23, 2022

Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of -19.30% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

GBT Reports Fourth Quarter and Full Year 2021 Financial Results

Achieved Oxbryta® (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year Executed on key growth opportunities highlighted by pediatric label expansion in the U.S., marketing authorization for ages 12 and over in the EU, and advancement of R&D pipeline Strong balance sheet with cash and investments totaling $734.8 million at year end Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 23, 2022 (GLOBE

Yahoo | February 23, 2022

Read More 'GBT' Stories Here

GBT Price Returns

1-mo 36.69%
3-mo -3.76%
6-mo 16.98%
1-year -0.03%
3-year -38.45%
5-year 16.08%
YTD 14.42%
2021 -32.42%
2020 -45.52%
2019 93.64%
2018 4.32%
2017 172.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4504 seconds.